These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 24118826)
1. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Sinibaldi S; Guzzo I; Piras R; Bresin E; Emma F; Dello Strologo L Pediatr Transplant; 2013 Dec; 17(8):E177-81. PubMed ID: 24118826 [TBL] [Abstract][Full Text] [Related]
2. Posttransplant recurrence of atypical hemolytic uremic syndrome. Valoti E; Alberti M; Noris M J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880 [TBL] [Abstract][Full Text] [Related]
3. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Tran H; Chaudhuri A; Concepcion W; Grimm PC Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349 [TBL] [Abstract][Full Text] [Related]
4. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Noris M; Caprioli J; Bresin E; Mossali C; Pianetti G; Gamba S; Daina E; Fenili C; Castelletti F; Sorosina A; Piras R; Donadelli R; Maranta R; van der Meer I; Conway EM; Zipfel PF; Goodship TH; Remuzzi G Clin J Am Soc Nephrol; 2010 Oct; 5(10):1844-59. PubMed ID: 20595690 [TBL] [Abstract][Full Text] [Related]
5. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022 [TBL] [Abstract][Full Text] [Related]
6. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644 [TBL] [Abstract][Full Text] [Related]
7. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Noris M; Remuzzi G Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560 [TBL] [Abstract][Full Text] [Related]
8. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576 [TBL] [Abstract][Full Text] [Related]
9. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549 [TBL] [Abstract][Full Text] [Related]
11. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452 [TBL] [Abstract][Full Text] [Related]
12. A newly identified mutation in the complement factor I gene not associated with early post-transplant recurrence of atypical hemolytic-uremic syndrome: a case report. Ranghino A; Tognarelli G; Basso E; Messina M; Manzione AM; Daidola G; Segoloni GP Transplant Proc; 2013 Sep; 45(7):2785-7. PubMed ID: 24034049 [TBL] [Abstract][Full Text] [Related]
13. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Alberti M; Valoti E; Piras R; Bresin E; Galbusera M; Tripodo C; Thaiss F; Remuzzi G; Noris M Am J Transplant; 2013 Aug; 13(8):2201-6. PubMed ID: 23731345 [TBL] [Abstract][Full Text] [Related]
14. Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature. Milan Manani S; Virzì GM; Giuliani A; Clementi A; Brocca A; Dissegna D; Martino F; d''Amore ESG; Ronco C Nephron; 2017; 136(3):245-253. PubMed ID: 28419995 [TBL] [Abstract][Full Text] [Related]
17. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Frémeaux-Bacchi V Biol Aujourdhui; 2013; 207(4):231-40. PubMed ID: 24594571 [TBL] [Abstract][Full Text] [Related]
18. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C; J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974 [TBL] [Abstract][Full Text] [Related]
19. [Atypical HUS caused by complement-related abnormalities]. Yoshida Y; Matsumoto M Rinsho Ketsueki; 2015 Feb; 56(2):185-93. PubMed ID: 25765799 [TBL] [Abstract][Full Text] [Related]
20. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Hirt-Minkowski P; Schaub S; Mayr M; Schifferli JA; Dickenmann M; Frémeaux-Bacchi V; Steiger J Nephrol Dial Transplant; 2009 Nov; 24(11):3548-51. PubMed ID: 19633317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]